Today: 20 May 2026
Experian shares steady after 19-month low — what the stock is pricing in now
22 January 2026
1 min read

Experian shares steady after 19-month low — what the stock is pricing in now

London, Jan 22, 2026, 09:15 GMT — Regular session

Experian (EXPN.L) shares held steady in early London trading Thursday, edging up roughly 0.1% to 3,072 pence after a steep drop the previous day. The stock moved within a 3,066 to 3,116 pence band.

Wednesday’s drop felt more like a reaction to impatience than a straightforward earnings miss. Investors were clearly expecting an upgrade to full-year guidance, not a steady forecast. Shares slid to a 19-month low, tumbling as much as 7% after Experian left its annual outlook unchanged. The stock has now fallen roughly 20% over the past year. Andrew Ripper, an analyst at Panmure Liberum, pointed to a weak U.S. dollar, the possibility of new U.S. limits on credit card interest rates, and fresh competition from Fair Isaac as ongoing concerns.

Experian slipped 4.87% to 30.70 pounds on Wednesday, lagging behind a modestly stronger FTSE 100, MarketWatch data shows.

The selloff hit despite Experian posting solid momentum in its fiscal third quarter, ending Dec. 31. Revenue climbed 12% on actual exchange rates and 10% at constant currency. Organic revenue — excluding currency effects and acquisitions — rose 8%, with full-year guidance unchanged. CEO Brian Cassin said, “We delivered strong Q3 growth… all in-line with our expectations.” Experian plans to release full-year results on May 20. Experian

Jefferies analyst Allen Wells took a cautious stance, noting that “3Q organic revenue growth of 8% is in line with expectations and underlying trends remain solid.” The note also highlighted Experian’s reaffirmation of its FY26 guidance, which anticipates total revenue growth of 11% and organic growth of 8%. The company kept its margin outlook steady, aiming for a 30–50 basis point improvement excluding foreign exchange (a basis point equals one-hundredth of a percentage point). uk.advfn.com

Investors will be watching closely to see if Wednesday’s selloff reflected positioning rather than underlying fundamentals. Experian’s results hinge on volumes in credit checks, mortgage inquiries, and fraud screenings—all of which can shift rapidly based on lender appetite and policy cues.

The company’s update highlighted strength in North America, but business-to-business growth stalled in Latin America and the UK and Ireland—an indication to some traders that regional performance remains uneven.

Competition is heating up. Fair Isaac’s move to sell credit scores straight to mortgage lenders threatens to cut out the bureaus as middlemen, stirring debate about how much room the sector has left to grow.

The downside is straightforward. Should U.S. lending momentum stall once more, or if policy changes start to hurt card economics, volume-driven revenue risks taking a hit just as the market pushes for upgrades rather than stability.

Traders are now focused on whether Experian can bounce back from Wednesday’s dip without offering new guidance. The key date ahead is May 20, when the full-year results drop—expect any remarks on U.S. consumer credit to influence sentiment long before that.

Stock Market Today

  • OpenAI Leads AI IPO Race as Confidential Filing Imminent
    May 20, 2026, 4:03 PM EDT. OpenAI has surged ahead of rival Anthropic as the favorite to launch the first initial public offering (IPO) among private AI firms. Prediction markets flipped following reports that OpenAI plans a confidential IPO filing as soon as this week, boosting its chances to 83% from 32%. Anthropic's probability of beating OpenAI has dropped significantly. Wedbush analyst Dan Ives emphasized the importance of being first to public markets in the competitive AI sector, citing valuation and investor engagement advantages. OpenAI's momentum follows a recent court victory and impending regulatory filings, despite previous investor concerns due to spending and leadership uncertainties. Meanwhile, Anthropic's Claude AI models and strong enterprise growth had recently made it a frontrunner, with a private valuation near $900 billion.

Latest articles

Bradesco Shares Up, Big Test Ahead for Brazil’s Bank Rally

Bradesco Shares Up, Big Test Ahead for Brazil’s Bank Rally

20 May 2026
Banco Bradesco’s preferred shares rose 3.28% to R$17.96 on Wednesday, outperforming the Ibovespa’s 2.12% gain as Brazilian bank stocks rebounded. Bradesco reported first-quarter recurring net income of R$6.8 billion, up 16.1% year-on-year, but loan-loss provisions increased 26.5% to R$9.7 billion. The Selic rate remains at 14.5% after recent cuts, with inflation expectations rising.
Norwegian Cruise Line Gains 9% as Oil Drops, Fuel Still in Focus

Norwegian Cruise Line Gains 9% as Oil Drops, Fuel Still in Focus

20 May 2026
Norwegian Cruise Line Holdings shares rose 9.2% to $16.15 Wednesday afternoon, rebounding after a four-day slide as oil prices dropped nearly 6%. Director Jose E. Cil bought 15,000 shares this week, according to an SEC filing. UBS cut its price target on the stock to $17. Norwegian recently lowered its 2026 earnings forecast and said net yield would fall 3% to 5%.
AT&T Shares Fall as Fiber Expansion, Cash Vow, Satellite Strategy Under Scrutiny

AT&T Shares Fall as Fiber Expansion, Cash Vow, Satellite Strategy Under Scrutiny

20 May 2026
AT&T shares fell 0.3% to $24.91 Wednesday, trailing a broader Wall Street rally led by chip stocks. The company reaffirmed its second-quarter free cash flow target of $4.0–$4.5 billion and plans to return over $45 billion to shareholders from 2026 to 2028. CEO John Stankey told investors fiber expansion remains a focus, with 7 million new passings expected this year.
BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”
Previous Story

BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data
Next Story

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Go toTop